mAbs targeting CCL2 appear to be well tolerated and cause minimal adverse side effects in human patients.123 Surprisingly, no improvement in clinical outcome was observed in prostate cancer patients treated with a monoclonal anti‐CCL2 Ab, although the Ab may have been ineffective at neutralizing CCL2.123 A recent clinical trial demonstrated the safety of a small molecule CCR2 antagonist in advanced pancreatic cancer patients,124 which represents a promising alternative to Ab‐based therapies. Here, CCL2 is linked to prostate cancer.